62 Functional characterisation of peroxisome proliferator-activated receptor gamma (PPARγ) in bovine blastocyst development and early trophectoderm formation

2022 ◽  
Vol 34 (2) ◽  
pp. 267
Author(s):  
M. McGraw ◽  
B. Daigneault
2021 ◽  
Vol 33 (2) ◽  
pp. 156
Author(s):  
A. C. Quiroga ◽  
C. de Frutos ◽  
E. Zurita ◽  
P. Bermejo-Álvarez

Prostaglandins (PGs) are lipid signalling molecules that play critical roles in gestation by promoting corpus luteus maintenance or luteolysis, and have been suggested to play other roles in early pregnancy, including embryo–maternal crosstalk. The signalling roles of PGs and other lipids are often mediated by peroxisome proliferator-activated receptors (PPARs), transcription factors that regulate the expression of other genes through PPAR-responsive elements. PPARG is a PPAR expressed by bovine pre-implantation embryos whose inhibition by morpholino intrauterine infusion has been reported to impair embryo development. As this approach causes PPARG depletion in both conceptus and uterus, it is unknown whether PPARG-mediated signalling in the embryo is required for embryo development. The objective of this study was to determine whether PPARG is required for blastocyst formation. For that aim, we have evaluated embryo development in PPARG knockout (KO) bovine embryos generated by CRISPR-Cas9 technology. Invitro matured oocytes were allocated in two groups: one was injected with mRNA encoding for Cas9 and sgRNA against PPARG to generate KO embryos (C+G, n=191) and the other was injected with mRNA alone (C, n=148), serving as a microinjection control generating only wild-type embryos. Following fertilization, embryos were allowed to develop to Day 8 blastocysts invitro. No differences were found in cleavage and blastocyst rates between both groups (cleavage 78.5±3.4 vs. 78.4±4.2; Day 7 blastocyst 17.3±3.9 vs. 10.8±2.9; Day 8 blastocyst 20.4±6.2 vs. 16.9±4.7; C+G vs. C; mean±s.e.m.; ANOVA P>0.05). Blastocysts of the C+G group were genotyped by clonal sequencing to determine which embryos in the C+G group were KO (i.e. harboured only frame-disrupting, KO alleles). Twenty-eight out of the 32 blastocysts analysed were edited (87.5%), of which 6 (18.8%) were KO. These results show that PPARG is not required for blastocyst formation, because KO embryos develop to that stage, but do not rule out a possible role in further developmental stages.


1998 ◽  
Vol 159 (3) ◽  
pp. 429-439 ◽  
Author(s):  
B Lohrke ◽  
T Viergutz ◽  
SK Shahi ◽  
R Pohland ◽  
K Wollenhaupt ◽  
...  

A prominent functional change during differentiation of lutein cells from follicular thecal and granulosa cells is an enhanced production and secretion of progestins. The regulation of this process is not fully understood but may be associated with the expression of transcription factors which activate genes, products of which are involved in pathways of the cholesterol and lipid metabolism. As peroxisome proliferator-activated receptors (PPARs) play a role in both pathways, we were interested in the expression of PPARgamma, a PPAR form which is involved in adipogenic differentiation. First, we were able to show the expression of PPARgamma in bovine lutein cells (day 12 of the ovarian cycle) at the mRNA and protein level by imaging, flow cytometry and blot analysis, and secondly a role of PPARgamma in the secretion of progesterone. The cells (24 h culture) responded dose dependently by increasing progesterone secretion (up to 1.5-fold of the basal level) to an endogenous ligand of PPARgamma, 15-deoxy-delta12,14 prostaglandin J2 (15-dPGJ2) and to the thiazolidinedione ciglitizone. Aurintricarboxylic acid (ATA) was found to reduce the intracellular PPARgamma level and to promote cell cycle progress, indicating that ATA can be used as a tool for experimental changes of PPARgamma proteins in intact cells and for studying the physiological consequences. The ATA-mediated decrease of PPARgamma was accompanied by reduced progesterone production and a progression of the cell cycle, suggesting a function of PPARgamma in both processes. The response to ATA was abrogated by a high dose (>490 nM) of 15-dPGJ2, suggesting that 15-dPGJ2 exerts its effect on steroidogenic activity via PPARgamma and that the 15-dPGJ2-PPARgamma system plays a role in the maintenance of a differentiated quiescent stage in lutein cells.


Sign in / Sign up

Export Citation Format

Share Document